Two PD Research Organisations Set to Merge

The Boards of Directors of the National Parkinson Foundation (NPF) and the Parkinson’s Disease Foundation (PDF) have announced that they have signed a letter of intent (LOI) to merge the two non-profit organisations. Both NPF and PDF have a strong track record of funding promising scientific research while enhancing patient care for people living with Parkinson’s disease. The Boards of both organisations recognise the potential of the combined entity to be a dynamic and comprehensive “next generation” organisation. The organisations anticipate signing definitive documents after completion of due diligence and closing as soon as possible thereafter.

“It is this type of teamwork that will ultimately defeat Parkinson’s and hopefully wipe it off the face of the earth.”

“The prospective merger of these two organisations in the US brings together two of the most influential patient bodies in North America. The move suggests that people engaged in trying to improve the lives of people with Parkinson’s are now pulling together more as a team. It is this type of teamwork that will ultimately defeat Parkinson’s and hopefully wipe it off the face of the earth. We look forward to working ever closer with our colleagues in the States to ensure this happens as soon as possible." said Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust.

How can we collect relevant data from people with Parkinson's to allow experiences to drive the research agenda - How do we engage sufficient numbers of people in recording information about themselves - What controls do we need in place?

Tom Isaacs, president of The Cure Parkinson's Trust, received an inaugural honour at the World Parkinson Congress in Portland Oregon today - for dedication and outstanding contribution in his work for the Parkinson's community.

Most read

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

The Michael J. Fox Foundation, Van Andel Research Institute and The Cure Parkinson’s Trust announced plans to collaborate on the clinical development of nilotinib in preliminary studies as a treatment for Parkinson’s.